Advertisement

Factors contributing to fluctuations of the dopaminergic nigro-striatal feedback system in Parkinson’s disease

  • P. Riederer
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 27)

Summary

The experience that the supplementation of depleted dopamine in the nigro-striatal system of parkinsonian patients with L-dopa improves the clinical triad, akinesia, rigidity and tremor, mainly applies to long-term treatment in the early phase of Parkinson’s disease. Complications in motor performance, like on-off response, wearing-off phenomena, peak-dose dyskinesia, biphasic dyskinesia, off-period dystonia and others, after more than 3 to 5 years following the onset of treatment indicate fluctuations in the dopaminergic feedback control system. It is suggested that these complications are due to progressive presynaptic degeneration and late changes in postsynaptic receptor amplification. However, as fluctuations are not imperative in all patients, an important additional aspect seems to be the topography of denervation, which involves different portions of the striatum to varying degrees. Location and extent of denervation are criteria which appear to have predictive value for the malignancy of the disease, the therapeutic response of drugs and complications in long-term treatment.

Keywords

Dopamine Agonist Rostral Part Postsynaptic Receptor Decarboxylase Inhibitor Amantadine Sulfate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Birkmayer W, Riederer P, Youdim MBH (1979) Distinction between benign and malignant type of Parkinson’s disease. Clin Neurol Neurosurg 158: 81–83Google Scholar
  2. Birkmayer W, Riederer P (1985) Die Parkinson-Krankheit, 2nd edn. Springer, Wien New YorkCrossRefGoogle Scholar
  3. Brücke T, Danielczyk W, Simanyi M, Sofie E, Riederer P (1987) Terguride: partial dopamine agonist in the treatment of Parkinson’s disease. In: Yahr MD, Bergmann KJ (eds) Advances in neurology. Raven Press, New York, pp 573–576Google Scholar
  4. Carlsson A (1983) Are “On-off” effects during chronic L-dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway? J Neural Transm [Suppl] 19: 153–161Google Scholar
  5. Clark D, Hjorth S, Carlsson A (1985) Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. J Neural Transm 62: 171–207PubMedCrossRefGoogle Scholar
  6. Corsini GU, Horowski R, Reiner E, del Zompo M (1984) Treatment of Parkinson’s disease with a dopamine partial agonist. Clin Neuropharmacol 7: 950–951CrossRefGoogle Scholar
  7. Danielczyk W (1973) Die Behandlung von akinetischen Krisen. Med Welt 24: 1278–1282PubMedGoogle Scholar
  8. Goldstein M, Lieberman A, Meiler E (1985) A possible molecular mechanism for the antiparkinsonian action of bromocriptine in combination with levodopa. TIPS (Nov.) 436–437Google Scholar
  9. Guttman M, Seeman P, Reynolds GP, Riederer P, Jellinger K, Tourtellotte WW (1986) Dopamine D 2 receptor density remains constant in treated Parkinson’s disease. Ann Neurol 19: 487–492CrossRefGoogle Scholar
  10. Hardie RJ, Malcolm SL, Lees AJ, Stern GM, Allen JG (1986) The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson’s disease who exhibit on-off fluctuations. Br J Clin Pharmacol 22: 429–436PubMedCrossRefPubMedCentralGoogle Scholar
  11. Hornykiewicz O, Kish SJ (1986) Biochemical pathophysiology of Parkinson’s disease. In: Yahr MD, Bergmann KJ (eds) Advances in neurology. Raven Press, New York, pp 19–34Google Scholar
  12. Jellinger K (1986) Overview of morphological changes in Parkinson’s disease. In: Yahr MD, Bergmann KJ (eds) Advances in neurology. Raven Press, New York, pp 1–18Google Scholar
  13. Kapfhammer HP, Kuss HJ, Eben E, Rüther E (1985) L-dopa infusion experiments in combination with the L-dopa-decarboxylase inhibitors benserazide and carbidopa: L- dopa metabolism and neuroendocrinological effects. Pharmacopsychiat 18: 143–144Google Scholar
  14. Karobath M (1985) Neue Aspekte in der Pharmakotherapie des M. Parkinson. In: Schna- berth G, Auff E (eds) Das Parkinson-Syndrom. Proceedings, Symposium 1984. Wissenschaftlicher Dienst “Roche”, Basle, pp 211–216Google Scholar
  15. Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277: 93–96PubMedCrossRefGoogle Scholar
  16. Marsden CD, Parkes JD, Quinn N (1982) Fluctuations of disability in Parkinson’s disease: clinical aspects. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworth, London, pp 86–122Google Scholar
  17. Muenter MD, Sharpless NS, Tyce GM, Darley L (1977) Patterns of dystonia (“I-D-I” and “D-I-D”) in response to L-dopa therapy of Parkinson’s disease. Mayo Clin Proc 52: 163–174PubMedGoogle Scholar
  18. Poewe WH, Lees AJ, Stern GM (1986) Treatment of motor fluctuations in Parkinson’s disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations. Clin Neuropharmacol 9: 430–439PubMedCrossRefGoogle Scholar
  19. Riederer P, Rausch WD, Birkmayer W, Jellinger K, Seeman D (1978) CNS modulation of adrenal tyrosine hydroxylase in Parkinson’s disease and metabolic encephalopathies. J Neural Transm [Suppl] 14: 121–132Google Scholar
  20. Riederer P (1986) Neurobiochemische Aspekte zur Progression der Parkinson-Krankheit: Post-mortem Befunde und MPTP-Modell. In: Fischer PA (ed) Spätsyndrome der Parkinson-Krankheit. Proceedings, Parkinson-Symposium 1986, Frankfurt. Wissenschaftlicher Dienst “Roche”, Basle, pp 37–48Google Scholar
  21. Rinne UK (1986) The importance of an early combination of a dopamine agonist and levodopa in the treatment of Parkinson’s disease. In: Van Manen J, Rinne UK (eds) Lisuride: a new dopamine agonist and Parkinson’s disease. Proceedings of a symposium, Berlin 1985. Excerpta Medica, Amsterdam, pp 64–71Google Scholar
  22. Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32: 229–313PubMedGoogle Scholar
  23. Seeman P, Guan HC, Bergeron C, Reynolds GP, Bird ED, Riederer P, Jellinger K, Tourtellotte WW (1987) Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer’s, Parkinson’s, and Huntington’s diseases. Neuropsychopharmacology, in pressGoogle Scholar
  24. Wesemann W (1984) Aspekte zum Wirkmechanismus von Amantadin. In: Danielczyk W, Wesemann W (eds) Amantadin-Workshop. Edition Materia Medica, Socio-Medico Verlag, GräfelfingGoogle Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • P. Riederer
    • 1
  1. 1.Clinical Neurochemistry Section, Department of PsychiatryUniversity ClinicWürzburgFederal Republic of Germany

Personalised recommendations